Glycans, galectins, and HIV-1 infection

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 133-148

  Sato, Sachiko ^a   Ouellet, Michel ^a   St Pierre, Christian ^a   Tremblay, Michel J ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Galectin; Glycobiology; HIV 1; Lectin

Indexed keywords

ANTIRETROVIRUS AGENT; GALECTIN; GALECTIN 1; GALECTIN 3; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; LECTIN; MEMBRANE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; SEXUAL TRANSMISSION; VIRUS ISOLATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860233524     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06475.x     Document Type: Review

References (125)

1. UNAIDS, J.U.N.P.o.H.A. 2009. 2009 AIDS Epidemic Update. Joint United Nations Programme on HIV/AIDS. Geneva, Switzerland.
2. UNAIDS, J.U.N.P.o.H.A. 2010. Global report: UNAIDS report on the global AIDS epidemic 2010. Available at: Accessed 23 Nov 2010.
3. Weiss, R.A. 2001. Gulliver's travels in HIVland. Nature 410: 963-967.
4. Freed, E.O. & Martin M.A. 2007. HIVs and their replication. In Fields Virology, 5th ed. D.M. Knipe & P.M. Howley, Eds.: 2107-2185. Lippincott Williams & Wilkins. Philadelphia.
5. Zhu, X., C. Borchers, R.J. Bienstock & K.B. Tomer. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204.
6. Scanlan, C.N., J. Offer, N. Zitzmann & R.A. Dwek. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038-1045.
7. Tremblay, M.J., J.F. Fortin & R. Cantin. 1998. The acquisition of host-encoded proteins by nascent HIV-1. Immunol. Today 19: 346-351.
8. Ugolini, S., I. Mondor & Q.J. Sattentau. 1999. HIV-1 attachment: another look. Trends Microbiol. 7: 144-149.
9. Cantin, R., S. Methot & M.J. Tremblay. 2005. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J. Virol. 79: 6577-6587.
10. Zhu, P., J. Liu, J. Bess, Jr., et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847-852.
11. Pantophlet, R. & D.R. Burton. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24: 739-769.
12. Leonard, C.K., M.W. Spellman, L. Riddle, et al. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265: 10373-10382.
13. Li, H., C.F. Xu, S. Blais, et al. 2009. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J. Immunol. 182: 6369-6378.
14. Yuen, C.T., S.A. Carr & T. Feizi. 1990. The spectrum of N-linked oligosaccharide structures detected by enzymic microsequencing on a recombinant soluble CD4 glycoprotein from Chinese hamster ovary cells. Eur. J. Biochem. 192: 523-528.
15. Pang, P.C., H.R. Morris, S.M. Haslam, et al. 2007. Glycomics analysis of HIV-1 gp120 glycoforms. Glycobiology 17: 1274.
16. St-Pierre, C., H. Manya, M. Ouellet, et al. 2011. Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. J. Virol. 85: 11742-11751.
17. Bonomelli, C., K.J. Doores, D.C. Dunlop, et al. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: e23521.
18. Doores, K.J., C. Bonomelli, D.J. Harvey, et al. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107: 13800-13805.
19. Ouellet, M., S. Mercier, I. Pelletier, et al. 2005. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J. Immunol. 174: 4120-4126.
20. Wyatt, R., P.D. Kwong, E. Desjardins, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
21. Chen, B., E.M. Vogan, H. Gong, et al. 2005. Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. Structure 13: 197-211.
22. Calarese, D., C. Scanlan, H.-K. Lee, et al. 2006. Toward a carbohydrate-based HIV-1 vaccine. In Carbohydrate Drug Design, 161-185. American Chemical Society. Washington.
23. Astronomo, R.D. & D.R. Burton. 2010. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug. Discov. 9: 308-324.
24. Agrawal-Gamse, C., R.J. Luallen, B. Liu, et al. 2011. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J. Virol. 85: 470-480.
25. Geijtenbeek, T.B., D.S. Kwon, R. Torensma, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
26. de Witte, L., A. Nabatov, M. Pion, et al. 2007. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13: 367-371.
27. Lambert, A.A., C. Gilbert, M. Richard, et al. 2008. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 112: 1299-1307.
28. Piguet, V. & R.M. Steinman. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28: 503-510.
29. Wu, L. & V.N. KewalRamani. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6: 859-868.
30. Bates, E.E., N. Fournier, E. Garcia, et al. 1999. APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif. J. Immunol. 163: 1973-1983.
31. Hildreth, J.E. & R.J. Orentas. 1989. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 244: 1075-1078.
32. Arthos, J., C. Cicala, E. Martinelli, et al. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9: 301-309.
33. Cicala, C., J. Arthos & A.S. Fauci. 2011. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J. Transl. Med. 9(Suppl. 1): S2.
34. Bobardt, M.D., A.C. Saphire, H.C. Hung, et al. 2003. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18: 27-39.
35. Gallay, P. 2004. Syndecans and HIV-1 pathogenesis. Microbes. Infect. 6: 617-622.
36. de Witte, L., M. Bobardt, U. Chatterji, et al. 2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U S A. 104: 19464-19469.
37. Mercier, S., C. St-Pierre, I. Pelletier, et al. 2008. Galectin-1 promotes HIV-1 infectivity in macrophages through stabilization of viral adsorption. Virology 371: 121-129.
38. St-Pierre, C., M. Ouellet, D. Giguere, et al. 2012. Galectin-1 specific inhibitors as a new class of compounds to treat HIV-1 infection. Antimicrob. Agents Chemother. 56: 154-162.
39. St-Pierre, C., M. Ouellet, M.J. Tremblay & S. Sato. 2010. Galectin-1 and HIV-1 infection. Methods Enzymol. 480: 267-294.
40. Keele, B.F. & C.A. Derdeyn. 2009. Genetic and antigenic features of the transmitted virus. Curr. Opin. HIV AIDS 4: 352-357.
41. Salazar-Gonzalez, J.F., M.G. Salazar, B.F. Keele, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206: 1273-1289.
42. Grivel, J.C., R.J. Shattock & L.B. Margolis. 2011. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J. Transl. Med. 9 (Suppl. 1): S6.
43. Kwong, P.D., R. Wyatt, Q.J. Sattentau, J. Sodroski et al. 2000. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74: 1961-1972.
44. Moulard, M., H. Lortat-Jacob, I. Mondor, et al. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74: 1948-1960.
45. Derdeyn, C.A., J.M. Decker, F. Bibollet-Ruche, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
46. Liu, Y., M.E. Curlin, K. Diem, et al. 2008. Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology 374: 229-233.
47. Alexander, M., R. Lynch, J. Mulenga, et al. 2010. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J. Virol. 84: 4100-4104.
48. Zhang, Z., T. Schuler, M. Zupancic, et al. 1999. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286: 1353-1357.
49. Haase, A.T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
50. van Montfort, T., D. Eggink, M. Boot, et al. 2011. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J. Immunol. 187: 4676-4685.
51. Cicala, C., E. Martinelli, J. P. McNally, et al. 2009. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106: 20877-20882.
52. European Study Group on Heterosexual Transmission of HIV. 1992. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 304: 809-813.
53. Leynaert, B., A.M. Downs & I. de Vincenzi. 1998. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 148: 88-96.
54. Varghese, B., J.E. Maher, T.A. Peterman, et al. 2002. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex. Transm. Dis. 29: 38-43.
55. Boily, M.C., R.F. Baggaley, L. Wang, et al. 2009. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect. Dis. 9: 118-129.
56. Shepard, C.W., E.P. Simard, L. Finelli, et al. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28: 112-125.
57. Piot, P., C. Goilav & E. Kegels. 1990. Hepatitis B: transmission by sexual contact and needle sharing. Vaccine 8(Suppl.): S37-40; discussion S41-33.
58. Mattapallil, J.J., D.C. Douek, B. Hill, et al. 2005. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
59. J.M. Brenchley, T.W. Schacker, L.E. Ruff, et al. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200: 749-759.
60. Veazey, R.S., M. DeMaria, L.V. Chalifoux, et al. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427-431.
61. Hel, Z., J.R. McGhee & J. Mestecky. 2006. HIV infection: first battle decides the war. Trends Immunol. 27: 274-281.
62. Keele, B.F., E.E. Giorgi, J.F. Salazar-Gonzalez, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105: 7552-7557.
63. Mondor, I., S. Ugolini & Q.J. Sattentau. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72: 3623-3634.
64. Karlsson Hedestam, G.B., R.A. Fouchier, S. Phogat, et al. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6: 143-155.
65. Haase, A.T. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5: 783-792.
66. McMichael, A. J., P. Borrow, G.D. Tomaras, et al. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10: 11-23.
67. Shattock, R.J. & J.P. Moore. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1: 25-34.
68. Bi, S., P.W. Hong, B. Lee & L.G. Baum. 2011. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. U. S. A. 108: 10650-10655.
69. Hirabayashi, J. & K. Kasai. 1993. The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 3: 297-304.
70. Klysov, A.A., Z.J. Witczak & D. Platt. 2008. Galectins. John Wiley & Sons, Inc. Hoboken, NJ.
71. Leffler, H. 2004. Special issue on galectins. Glycoconj. J. 19: 433-638.
72. Rabinovich, G.A. & M.A. Toscano. 2009. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9: 338-352.
73. Sato, S. & J. Nieminen. 2004. Seeing strangers or announcing "danger": galectin-3 in two models of innate immunity. Glycoconj. J. 19: 583-591.
74. Nieminen, J., A. Kuno, J. Hirabayashi & S. Sato. 2007. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J. Biol. Chem. 282: 1374-1383.
75. Nieminen, J., C. St-Pierre & S. Sato. 2005. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J. Leukoc. Biol. 78: 1127-1135.
76. Rabinovich, G.A., M.A. Toscano, S.S. Jackson & G.R. Vasta. 2007. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17: 513-520.
77. Liu F.T. & G.A. Rabinovich. 2010. Galectins: regulators of acute and chronic inflammation. Ann. N. Y. Acad. Sci. 1183: 158-182.
78. Sato, S., C. St-Pierre, P. Bhaumik & J. Nieminen. 2009. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol. Rev. 230: 172-187.
79. Vasta, G.R. 2009. Roles of galectins in infection. Nat. Rev. Microbiol. 7: 424-438.
80. Rabinovich, G., L. Castagna, C. Landa, et al. 1996. Regulated expression of a 16-kd galectin-like protein in activated rat macrophages. J. Leukoc. Biol. 59: 363-370.
81. Baum, L.G., M. Pang, N.L. Perillo, et al. 1995. Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells. J. Exp. Med. 181: 877-887.
82. Zuniga, E., G.A. Rabinovich, M.M. Iglesias & A. Gruppi. 2001. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J. Leukoc. Biol. 70: 73-79.
83. Blaser, C., M. Kaufmann, C. Muller, et al. 1998. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol. 28: 2311-2319.
84. Dettin, L., N. Rubinstein, A. Aoki, et al. 2003. Regulated expression and ultrastructural localization of galectin-1, a proapoptotic beta-galactoside-binding lectin, during spermatogenesis in rat testis. Biol. Reprod 68: 51-59.
85. Jeschke, U., T. Reimer, C. Bergemann, et al. 2004. Binding of galectin-1 (gal-1) on trophoblast cells and inhibition of hormone production of trophoblast tumor cells in vitro by gal-1. Histochem. Cell. Biol. 121: 501-508.
86. Stillman, B.N., D.K. Hsu, M. Pang, et al. 2006. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176: 778-789.
87. Toscano, M.A., L. Campagna, L.L. Molinero, et al. 2011. Nuclear factor (NF)-kappaB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol. Immunol. 48: 1940-1949.
88. Nio-Kobayashi, J., H., Takahashi-Iwanaga & T. Iwanaga. 2009. Immunohistochemical localization of six galectin subtypes in the mouse digestive tract. J. Histochem. Cytochem. 57: 41-50.
89. Singh, B.N., G.R. Hayes, J.J. Lucas, et al. 2009. Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Glycoconj. J. 26: 3-17.
90. Fichorova, R.N. 2009. Impact of T. vaginalis infection on innate immune responses and reproductive outcome. J. Reprod. Immunol. 83: 185-189.
91. Fogel, S., M. Guittaut, A. Legrand, et al. 1999. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology 9: 383-387.
92. Imbeault, M., R. Lodge, M. Ouellet & M.J. Tremblay. 2009. Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population. Virology 393: 160-167.
93. Sato, S. & R.C. Hughes. 1994. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J. Biol. Chem. 269: 4424-4430.
94. Sundblad, V., D.O. Croci & G.A. Rabinovich. 2011. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol. Histopathol 26: 247-265.
95. Lalancette-Hébert, M., G. Gowing, A. Simard, et al. 2007. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27: 2596-2605.
96. Liu, F.T. 2005. Regulatory roles of galectins in the immune response. Int. Arch. Allergy. Immunol. 136, 385-400.
97. Sato, S. 2002. Galectin as a molecule of danger signal, which could evoke immune response to infection. Trends Glycosci. Glycotechnol. 14: 285-301.
98. Wada, J., K. Ota, A. Kumar, et al. 1997. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J. Clin. Invest. 99: 2452-2461.
99. Matsumoto, R., H. Matsumoto, M. Seki, et al. 1998. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273: 16976-16984.
100. Krishnamoorthy, L., J.W. Bess, Jr., A.B. Preston, et al. 2009. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat. Chem. Biol. 5: 244-250.
101. Sparrow, C.P., H. Leffler & S.H. Barondes. 1987. Multiple soluble beta-galactoside-binding lectins from human lung. J. Biol. Chem. 262: 7383-7390.
102. Barondes, S.H., D.N. Cooper, M.A. Gitt & H. Leffler. 1994. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269: 20807-20810.
103. Rabinovich, G.A., L.G. Baum, N. Tinari, et al. 2002. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23: 313-320.
104. Hirabayashi, J., T. Hashidate, Y. Arata, et al. 2002. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim. Biophys. Acta. 1572: 232-254.
105. Stowell, S.R., C.M. Arthur, P. Mehta, et al. 2008. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 283: 10109-10123.
106. Stowell, S.R., S. Karmakar, C.J. Stowell, et al. 2007. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109: 219-227.
107. Sato, S. & R.C. Hughes. 1992. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J. Biol. Chem. 267: 6983-6990.
108. Pelletier, I. & S. Sato. 2002. Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope. J. Biol. Chem. 277: 17663-17670.
109. Pelletier, I., T. Hashidate, T. Urashima, et al. 2003. Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. J. Biol. Chem. 278: 22223-22230.
110. Toscano, M.A., G.A. Bianco, J.M. Ilarregui, et al. 2007. Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8: 825-834.
111. Lanteri, M., V. Giordanengo, N. Hiraoka, et al. 2003. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology 13: 909-918.
112. Sun, J., B. Barbeau, S. Sato, et al. 2002. Syncytium formation and HIV-1 replication are both accentuated by purified influenza and virus-associated neuraminidase. J. Biol. Chem. 277: 9825-9833.
113. Sun, J., B. Barbeau, S. Sato & M.J. Tremblay. 2001. Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process. Virology 284: 26-36.
114. Roggentin, P., B. Rothe, J.B. Kaper, et al. 1989. Conserved sequences in bacterial and viral sialidases. Glycoconj. J. 6: 349-353.
115. Roggentin, P., R. Schauer, L.L. Hoyer & E.R. Vimr. 1993. The sialidase superfamily and its spread by horizontal gene transfer. Mol. Microbiol. 9: 915-921.
116. Soong, G., A. Muir, M.I. Gomez, et al. 2006. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J. Clin. Invest. 116: 2297-2305.
117. Takasaki, S., K. Yamashita, K. Suzuki & A. Kobata. 1980. Structural studies of the sugar chains of cold-insoluble globulin isolated from human plasma. J. Biochem. 88: 1587-1594.
118. Takamoto, M., T. Endo, M. Isemura, et al. 1989. Structures of asparagine-linked oligosaccharides of human placental fibronectin. J. Biochem. 105: 742-750.
119. Varki, A., M.E. Etzler, R.D. Cummings & J.D. Esko. 2009. Discovery and classification of glycan-binding proteins. In Essentials of Glycobiology, 2nd ed. A. Varki, R.D. Cummings, J. Esko, H.H. Freeze, P. Stanley, C.R. G. Bertozzi, W. Hart, & M.E. Etzler, Eds.: 375-386. Cold Spring Harbor Laboratory Press. New York.
120. Nio-Kobayashi, J. & T. Iwanaga. 2010. Immunohistochemical localization of galectins in mouse genital tract. Kaibougaku Zasshi (Acta Anatomica Nipponica) 85: 58-59.
121. Argueso, P., A. Guzman-Aranguez, F. Mantelli, et al. 2009. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J. Biol. Chem. 284: 23037-23045.
122. Tejler, J., E. Tullberg, T. Frejd, et al. 2006. Synthesis of multivalent lactose derivatives by 1, 3-dipolar cycloadditions: selective galectin-1 inhibition. Carbohydr. Res. 341: 1353-1362.
123. Giguere, D., R. Patnam, M.A. Bellefleur, et al. 2006. Carbohydrate triazoles and isoxazoles as inhibitors of galectins-1 and -3. Chem. Commun. (Camb). 22: 2379-2381.
124. Giguere, D., S. Sato, St-Pierre, C., et al. 2006. Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: role of electrostatic potential at O-3. Bioorg. Med. Chem. Lett. 16: 1668-1672.
125. Giguere, D., M.A. Bonin, P. Cloutier, et al. 2008. Synthesis of stable and selective inhibitors of human galectins-1 and -3. Bioorg. Med. Chem. 16: 7811-7823.